Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | TOP2A | P11388 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22589662 | 0.88 | HSP90AA1 (0.38) | HSP90AA1TOP2AKDM4EALDH1A1PTBP1 | |
| SCHEMBL22589675 | 0.84 | HKDC1 (0.41) | HSP90AA1TOP2AKDM4EALDH1A1HTT | |
| SCHEMBL22589681 | 0.80 | NPC1 (0.46) | KDM4EALDH1A1RAB9ASMN1; SMN2MAOA | |
| SCHEMBL17963041 | 0.74 | KDM4E (0.50) | CHRNB2CHRNA4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22589328 | 0.74 | HSP90AA1 (0.36) | HSP90AA1TOP2AKDM4EALDH1A1PTBP1 | |
| SCHEMBL17987830 | 0.74 | HSP90AA1 (0.60) | HSP90AA1KDM4EALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22589679 | 0.74 | TOP2A (0.38) | HSP90AA1TOP2AKDM4EALDH1A1PTBP1 | |
| SCHEMBL24512428 | 0.73 | GRM5 (0.40) | — | |
| SCHEMBL22589676 | 0.73 | GRM5 (0.40) | — | |
| SCHEMBL22589677 | 0.73 | GRM5 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185827-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-06-16 | — | — | US | disclosed |
| US-10604480-B2 | (Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180002280-A1 | (THIO, OXO, AND SELENO) SEMICARBAZONE DERIVATIVES AND THEIR USE FOR TREATING CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016123242-A1 | (THIO)SEMICARBAZONE DERIVATIVES AND THEIR USE FOR TREATING CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604480-B2 | (Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer | TST, SCLY, GPX1 | CHRNB2 4782/4885CHRNA4 4762/4885HSP90AA1 1157/4885 |
| US-20220185827-A1 | PHARMACEUTICAL COMPOUNDS AND THERAPEUTIC METHODS | SLC30A5, SLC39A11, SLC30A7 | CHRNB2 4556/4885CHRNA4 4433/4885HSP90AA1 2676/4885 |
| US-20180002280-A1 | (THIO, OXO, AND SELENO) SEMICARBAZONE DERIVATIVES AND THEIR USE FOR TREATING CANCER | TST, SCLY, GPX1 | CHRNB2 4782/4885CHRNA4 4762/4885HSP90AA1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.